Business Wire

TX-SNOW-SOFTWARE

10.11.2022 15:01:39 CET | Business Wire | Press release

Share
Snow Software Launches New Capabilities to Help ITAM Teams Get Control of Costs in the Cloud

Snow Software, the global leader in technology intelligence, today announced new and enhanced capabilities to support IT leaders seeking to negotiate better contract terms, lower operating expenses and boost organizational-wide efficiencies during this period of macroeconomic uncertainty. The latest features offer a richer view of an organization’s IT investments and the impact to the business, providing new ways to optimize costs and ensure value of complex technologies like containers and cloud services. Container visibility, one of the newest innovations on the Snow Atlas platform, provides details on applications running in Kubernetes containers to identify cost savings.

“The macroeconomic environment is forcing organizations to seek a deeper understanding of how all areas of their business are performing,” said Sanjay Castelino, Chief Product and Customer Officer at Snow. “With large annual budgets devoted to IT spend, demonstrating return on investment for every technology purchase is vital for CIOs and IT teams. The latest release from Snow not only identifies how technology is used but also offers use cases to support more sustainable IT practices such as understanding the carbon footprint of devices. With IT environments more complex than ever, the intelligence Snow provides serves as the backbone for organizations seeking to get more control over IT spending and risk.”

Gaining Visibility of Container Environments
More than 70% of global organizations will use containerized applications by 2023, according to industry analysts. Widespread use of containers creates new barriers for organizations seeking to understand what is running in a container – let alone control costs.

The new container visibility feature available on Snow Atlas is designed to provide IT teams and IT asset managers (ITAM) details on what applications are running, how many containers are used in their environment, and how long containers have been running. In this release, the capability provides insights into Microsoft, Oracle and Red Hat standard containerized applications running in Kubernetes environments. Container visibility is available for Kubernetes environments running on major cloud services such as Amazon Web Services (AWS) and Microsoft Azure environments. This insight enables IT and ITAM teams to manage cost more efficiently.

Snow is inviting organizations with Kubernetes environments to use the functionality, with general availability of the capability aimed at early 2023.

Empowering ITAM to Partner with FinOps to Manage Rising Cloud Costs
To give a more complete picture of the end-to-end organizational tech stack, the latest release from Snow gives ITAM teams a spend snapshot across AWS and Azure in the terminology and views used by ITAM. With this new service – available to all Snow Atlas customers – ITAM teams have improved views of their organization’s spend profile in public cloud natively within their SAM tool. By building this feature natively within the existing SAM product, Snow makes it easier for ITAM to drive conversations about spend optimization with cloud stakeholders and FinOps teams.

For organizations with more mature cloud practices, FinOps or cloud operations practitioners, Snow Cloud Cost powered by Anodot provides greater depth of visibility, insights and analysis on public cloud spend, controls for budget management and spend allocation, detection of anomalies and recommendations for optimizing spend.

Enabling IT to Build a Sustainable Enterprise
Developing a more sustainable enterprise is a top priority for most CIOs. Snow makes it easier for IT teams to deliver on their sustainability goals. Organizations can leverage existing ITAM data, such as the laptop and desktop details, to assess their sustainability baseline. This sustainability intelligence report from Snow also includes curated information on how many certified sustainable devices exist, the spectrum of energy efficient devices and an evaluation of carbon emission reduction with on-premises to cloud shifts. The data provided by Snow enables CIOs and IT leaders to take proactive measures to actively manage and advance their sustainability initiatives.

Expanded Support to Reduce S/4HANA Migration Risks
With the end of maintenance for Business Suite 7 approaching, the migration to S/4HANA is a strategic imperative for many organizations. Snow is releasing new license intelligence, contract management and management dashboards for Snow Optimizer for SAP® Software to help offer further support with S/4HANA migrations. The new license intelligence capabilities allow organizations to easily simulate alternative license scenarios for both usage and authorization-based licensing, helping them decide on the most efficient and cost-effective migration strategy. In addition, new functionality allows for more transparent and secure management of an organization’s SAP environment by providing insight into license metrics and enhanced controls over contract management.

These new and enhanced capabilities follow several notable product milestones for Snow this year, including a new host of capabilities for Snow Atlas, a new partnership with Anodot to transform cloud cost management, verification on Oracle Database and Database Options and new enhancements for Snow Commander.

For more information or to request a demo, please visit www.snowsoftware.com.

About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005344/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye